UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

Akcea Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00972L 10 7

(CUSIP Number)

July 19, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-l(b)

x

Rule 13d-l(c)

o

Rule 13d-l(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 



 

CUSIP No.  00972L 10 7

 

 

1.

Names of Reporting Persons.
NOVARTIS PHARMA AG

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Switzerland

 

 

 

Number of
Shares
Beneficially by
Owned by
Each
Reporting
Person With:

5.

Sole Voting Power
0

 

6.

Shared Voting Power
6,250,000

 

7.

Sole Dispositive Power
0

 

8.

Shared Dispositive Power
6,250,000

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
6,250,000

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).  o

 

 

11.

Percent of Class Represented by Amount in Row (9)
9.7% (1)

 

 

12.

Type of Reporting Person (See Instructions)
CO

 


(1) Based on 64,197,879 shares of the Issuer’s common stock outstanding as of July 19, 2017 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus dated July 13, 2017 (the “Final Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 14, 2017 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (the “Securities Act”). The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 2,343,750 shares of Common Stock within 30 days from the date of the Final Prospectus.

 

2



 

Item 1.

 

(a)

Name of Issuer
Akcea Therapeutics, Inc.

 

(b)

Address of Issuer’s Principal Executive Offices
55 Cambridge Parkway, Cambridge, Massachusetts 02142

 

Item 2.

 

(a)

Name of Person Filing

This statement is filed on behalf of each of the following persons:

 

(i)   Novartis Pharma AG, with respect to shares held by it; and

 

(ii)  Novartis AG, as the publicly owned parent of Novartis Pharma AG, with respect to the shares held by Novartis Pharma AG.

 

The foregoing persons are hereinafter referred to collectively as the “Reporting Persons.”

 

(b)

Address of Principal Business Office or, if none, Residence:

The address of the principal business office of each of Novartis Pharma AG and Novartis AG is Lichtstrasse 35, 4056 Basel, Switzerland.

 

(c)

Citizenship

Novartis AG and Novartis Pharma AG are each corporations organized under the laws of Switzerland.

 

(d)

Title of Class of Securities

Common Stock, par value $0.001 per share

 

(e)

CUSIP Number

00972L 10 7

 

Item 3.

If this statement is filed pursuant to §§240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

 

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

 

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

 

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

 

(e)

o

An investment adviser in accordance with §240.13d-l(b)(l)(ii)(E);

 

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-l(b)(l)(ii)(F);

 

(g)

o

A parent holding company or control person in accordance with § 240.13d-l(b)(l)(ii)(G);

 

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j)

o

A non-U.S. institution in accordance with §240.13d-l(b)(l)(ii)(J).

 

(k)

o

Group, in accordance with §240.13d-l(b)(l)(ii)(K). If filing as a non-U.S. institution in accordance with

§240.13d-l(b)(l)(ii)(J), please specify the type of institution:____________________________

 

3



 

Item 4.

Ownership.

 

(a)

Amount beneficially owned:   

Novartis Pharma AG is the record owner of 6,250,000 shares of Common Stock of the Issuer. As the indirect parent of Novartis Pharma AG, Novartis AG may be deemed to beneficially own these securities.

 

(b)

Percent of class:  9.7%

Based on 64,197,879 shares of the Issuer’s common stock outstanding as of July 19, 2017 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus dated July 13, 2017 (the “Final Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 14, 2017 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (the “Securities Act”). The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 2,343,750 shares of Common Stock within 30 days from the date of the Final Prospectus.

 

(c)

Number of shares as to which the person has:

 

 

 

(i)

Sole power to vote or to direct the vote.

0

 

 

(ii)

Shared power to vote or to direct the vote.

of 6,250,000

 

 

(iii)

Sole power to dispose or to direct the disposition of.

0

 

 

(iv)

Shared power to dispose or to direct the disposition of.

of 6,250,000

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   o.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group

Not applicable.

 

Item 9.

Notice of Dissolution of Group

Not applicable.

 

4



 

Item 10.

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct

 

 

 

NOVARTIS PHARMA AG

 

 

 

 

 

By:

/s/ Jean-Baptiste Emery

 

Name: Jean-Baptiste Emery

 

Title: Authorized Signatory

 

 

 

 

 

By:

/s/ Stefan Thommen

 

Name: Stefan Thommen

 

Title: Authorized Signatory

 

 

 

 

 

NOVARTIS AG

 

 

 

 

 

By:

/s/ Christian Rehm

 

Name: Christian Rehm

 

Title:  Authorized Signatory

 

 

 

 

 

By:

/s/ Katja Roth Pellanda

 

Name: Katja Roth Pellanda

 

Title:  Authorized Signatory

 

5



 

INDEX EXHIBIT

 

SCHEDULE 13G

 

Exhibit Reference

 

Exhibit Description

 

 

 

A

 

Evidence of Signature Authority

 

 

 

B

 

Joint Filing Agreement

 

6



 

Exhibit A

 

Evidence of Signature Authority

 

Excerpt from Commercial Register of Novartis AG:

 

Commercial register of canton Basel-Stadt

 

 

CHE-103.867.266

Novartis AG

Basel

9

 

All data

 

In

 

Mo

 

Ca

 

Personal Data

 

Function

 

Signature

73

 

 

 

 

 

Kirsch, Harry Werner, deutscher Staatsangehöriger, in Therwil

 

member of the management

 

joint signature at two

73

 

 

 

 

 

Rehm, Christian Jakob, von Ruschein, in Muttenz

 

 

 

joint signature at two

73

 

 

 

 

 

Götz Staehelin, Dr. Claudia, von Basel, in Riehen

 

 

 

joint signature at two

73

 

 

 

86m

 

 

 

 

 

 

74

 

 

 

 

 

Schubert Santana, Isabelle Andrea, von Altstätten, in Therwil

 

 

 

joint signature at two

76

 

 

 

 

 

Baert, Steven Lodewijk Margareta Anna Katrien, belgischer Staatsangehöriger, in Arlesheim

 

member of the management

 

joint signature at two

 

 

76

 

 

 

Brokatzky-Geiger, Dr. Jürgen, deutscher Staatsangehöriger, in Lörrach (DE)

 

 

 

joint signature at two

76

 

 

 

84

 

 

 

 

 

 

76

 

 

 

 

 

Jones, Susan Elizabeth, australische Staatsangehörige, in Basel

 

 

 

joint signature at two

76

 

 

 

82

 

 

 

 

 

 

77

 

 

 

 

 

Weiss, Daniel Andreas, von Basel, in Biel-Benken

 

 

 

joint signature at two

 

 

78

 

 

 

Kaul, Siddharth, amerikanischer Staatsangehöriger, in Reinach BL

 

 

 

joint signature at two

 

 

80

 

88

 

 

 

 

 

 

82

 

 

 

 

 

Andrews, Prof. Dr. med. Nancy Catherine, amerikanische Staatsangehörige, in Chapel Hill (NC/US)

 

member of the board of directors

 

without signing rights

83

 

 

 

 

 

Penepent, Paul Lewis, amerikanischer Staatsangehöriger, in Basel

 

 

 

joint signature at two

84

 

 

 

 

 

Roth Pellanda, Katja Nicole, von Basel, in Basel

 

 

 

joint signature at two

84

 

 

 

 

 

Finnie, Nicholas James, britischer Staatsangehöriger, in Basel

 

 

 

joint signature at two

 

 

84

 

 

 

PricewaterhouseCoopers AG (CHE-393.441.652), in Basel

 

auditor

 

 

 

 

85

 

 

 

Landolt, Pierre, von Aarau, in Lissabon (PT)

 

member of the board of directors

 

without signing rights

 

 

86

 

 

 

Brupbacher, Dr. Oliver Mark, von Wädenswil, in Basel

 

 

 

joint signature at two

88

 

 

 

 

 

Büchner, Anthonius, niederländischer Staatsangehöriger, in Amsterdam (NL)

 

member of the board of directors

 

without signing rights

88

 

 

 

 

 

Doherty, Mary Elizabeth, britische Staatsangehörige, in Gerrards Cross (GB)

 

member of the board of directors

 

without signing rights

88

 

 

 

93m

 

 

 

 

 

 

89

 

 

 

 

 

Schreiner, Peter Christian, von Visp, in Muttenz

 

 

 

joint signature at two

 

 

90

 

 

 

Ehrat, Dr. Felix Rudolf, von Lohn SH, in Zug

 

member of the management

 

joint signature at two

92

 

 

 

94m

 

 

 

 

 

joint signature at two

92

 

 

 

 

 

Arnet, Thomas, von Arlesheim, in Arlesheim

 

 

 

 

92

 

 

 

 

 

Meyer, Christopher Allen, amerikanischer Staatsangehöriger, in Oberwil (BL)

 

 

 

joint signature at two

 

 

93

 

 

 

Emery, Jean-Baptiste, von Estavayer, in Fribourg

 

 

 

joint signature at two

 

 

94

 

 

 

van Houten, François, genannt Frans, niederländischer Staatsangehöriger, in Amstelveen (NL)

 

member of the board of directors

 

without signing rights

 

Basel, 25.07.2017 22:47

The information above is given with not commitment and is in no way legally binding.

 

7



 

Excerpt from Commercial Register of Novartis Pharma AG

 

Commercial register of canton Basel-Stadt

 

 

CHE-106.052.527

Novartis Pharma AG

Basel

5

 

All data

 

In

 

Mo

 

Ca

 

Personal Data

 

Function

 

Signature

1

 

 

 

9

 

 

 

 

 

 

1

 

 

 

16

 

 

 

 

 

 

1

 

 

 

26

 

 

 

 

 

 

1

 

 

 

 

 

Legowski, Sabina, von St. Gallen, in Pfeffingen

 

 

 

joint signature at two

1

 

 

 

 

 

Levi, Barbara, italienische Staatsangehörige, in Basel

 

 

 

joint signature at two

1

 

 

 

29

 

 

 

 

 

 

1

 

 

 

10

 

 

 

 

 

 

1

 

 

 

 

 

Mager, Knut, deutscher Staatsangehöriger, in Basel

 

 

 

joint signature at two

1

 

 

 

32

 

 

 

 

 

 

1

 

 

 

 

 

Marti Romero, Francisco Tadeo, spanischer Staatsangehöriger, in Basel

 

 

 

joint signature at two

1

 

 

 

32

 

 

 

 

 

 

1

 

 

 

32

 

 

 

 

 

 

1

 

 

 

 

 

Meier, Oliver Werner, deutscher Staatsangehöriger, in Auggen (DE)

 

 

 

joint signature at two

1

 

 

 

8

 

 

 

 

 

 

1

 

 

 

 

 

Mills, Jacqueline, britische Staatsangehörige, in Tagsdorf (FR)

 

 

 

joint signature at two

1

 

 

 

 

 

Moran-Adams, Lena, britische Staatsangehörige, in Basel

 

 

 

joint signature at two

1

 

 

 

2

 

 

 

 

 

 

1

 

 

 

 

 

Ortscheit, Ralph, von Basel, in Pfeffingen

 

 

 

joint signature at two

1

 

 

 

 

 

Oser, Markus Joseph, von Schönenbuch, in Basel

 

 

 

joint signature at two

1

 

 

 

 

 

Owens, Matt, amerikanischer Staatsangehöriger, in Oberwil BL

 

 

 

joint signature at two

1

 

 

 

38

 

 

 

 

 

 

1

 

 

 

 

 

Pfirter, Simone, von Pratteln, in Pratteln

 

 

 

joint signature at two

1

 

 

 

 

 

Pope, Gavin Daniel, britischer Staatsangehöriger, in Aesch BL

 

 

 

joint signature at two

1

 

 

 

11m

 

 

 

 

 

 

1

 

 

 

15

 

 

 

 

 

 

1

 

 

 

 

 

Rehm, Christian Jakob, von Ruschein, in Muttenz

 

 

 

joint signature at two

1

 

 

 

 

 

Roth, Claus Christian, deutscher Staatsangehöriger, in Basel

 

 

 

joint signature at two

1

 

 

 

33

 

 

 

 

 

 

1

 

 

 

 

 

Schade, Andreas, deutscher Staatsangehöriger, in Grenzach-Wyhlen (DE)

 

 

 

joint signature at two

1

 

 

 

32

 

 

 

 

 

 

1

 

 

 

 

 

Schneider, Fabienne, französische Staatsangehörige, in Oltingue (F)

 

 

 

joint signature at two

1

 

 

 

29

 

 

 

 

 

 

1

 

 

 

 

 

Sitzler Spicher, Lilly Monique, von Basel und Ueberstorf, in Allschwil

 

 

 

joint signature at two

1

 

 

 

23m

 

 

 

 

 

 

1

 

 

 

 

 

Steel, Michael, britischer Staatsangehöriger, in Binningen

 

 

 

joint signature at two

1

 

 

 

8

 

 

 

 

 

 

1

 

 

 

 

 

Sullivan, Marvelle, amerikanische Staatsangehörige, in Basel

 

 

 

joint signature at two

1

 

 

 

 

 

Thommen, Stefan, von Bubendorf, in Ramlinsburg

 

 

 

joint signature at two

1

 

 

 

 

 

Tougas, Gervais, kanadischer Staatsangehöriger, in Magglingen

 

 

 

joint signature at two

1

 

 

 

15

 

 

 

 

 

 

1

 

 

 

24

 

 

 

 

 

 

1

 

 

 

24

 

 

 

 

 

 

1

 

 

 

32

 

 

 

 

 

 

1

 

 

 

13m

 

 

 

 

 

 

1

 

 

 

 

 

Wipfli, Daniel, von Erstfeld, in Dübendorf

 

 

 

joint signature at two

1

 

 

 

32

 

 

 

 

 

 

 

Basel, 25.07.2017 22:48

Continuation on the following page

 

8



 

Commercial register of canton Basel-Stadt

 

 

CHE-106.052.527

Novartis Pharma AG

Basel

8

 

All data

 

In

 

Mo

 

Ca

 

Personal Data

 

Function

 

Signature

32

 

 

 

 

 

Sandschafer, Scott Anthony, amerikanischer Staatsangehöriger, in Bottmingen

 

 

 

joint signature at two

33

 

 

 

 

 

Baert, Steven Lodewijk Margareta Anna Katrien, belgischer Staatsangehöriger, in Arlesheim

 

 

 

joint signature at two

33

 

 

 

 

 

Orlandi, Nicola, italienischer Staatsangehöriger, in Riehen

 

 

 

joint signature at two

33

 

 

 

 

 

Takei, Dr. Naoki Daniel, von Wyssachen, in Rheinfelden

 

 

 

joint signature at two

33

 

 

 

 

 

Vall-Llossera Ferran, Jorge Juan, spanischer Staatsangehöriger, in Binningen

 

 

 

joint signature at two

 

 

34

 

 

 

Splisgardt, Dr. Marc, von Schaffhausen, in Binningen

 

 

 

joint signature at two

35

 

 

 

 

 

Bugnon, Bertrand Richard René, von Fribourg, in Belfaux

 

 

 

joint signature at two

35

 

 

 

 

 

de la Paz, Minerva Fernando, amerikanische Staatsangehörige, in Muttenz

 

 

 

joint signature at two

35

 

 

 

 

 

Schreiner, Peter Christian, von Visp, in Muttenz

 

 

 

joint signature at two

35

 

 

 

 

 

van Rijn, Petrus Cornelius Rolandus, niederländischer Staatsangehöriger, in Galgenen

 

 

 

joint signature at two

 

 

36

 

 

 

Turgut Noto, Saide Yeliz, türkische Staatsangehörige, in Pfeffingen

 

 

 

joint signature at two

 

 

37

 

 

 

Ehrat, Dr. Felix Rudolf, von Lohn SH, in Zug

 

member of the board of directors

 

joint signature at two

 

 

38

 

 

 

Heynen, Bruno, von Bellach, in Solothurn

 

 

 

joint signature at two

 

 

38

 

 

 

Roth Pellanda, Katja Nicole, von Basel, in Basel

 

secretary (out of the board)

 

joint signature at two

38

 

 

 

 

 

Bouwmeester, Antonius Johannes Maria, genannt Tewis, niederländischer Staatsangehöriger, in Freiburg (DE)

 

 

 

joint signature at two

38

 

 

 

 

 

Leuenberger, Matthias, von Melchnau, in Binningen

 

 

 

joint signature at two

38

 

 

 

 

 

von Arx, Gregor Johannes, von Zullwil, in Riehen

 

 

 

joint signature at two

 

 

39

 

 

 

Klemm, Christian, deutscher Staatsangehöriger, in Oberwil (BL)

 

 

 

joint signature at two

 

 

40

 

 

 

Emery, Jean-Baptiste, von Estavayer, in Fribourg

 

 

 

joint signature at two

 

 

40

 

 

 

Schubert Santana, Isabelle Andrea, von Altstätten, in Therwil

 

 

 

joint signature at two

 

Basel, 25.07.2017 22:48

The information above is given with not commitment and is in no way legally binding.

 

9



 

Exhibit B

 

Joint Filing Agreement

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Akcea Therapeutics, Inc. The undersigned hereby further agree that this Joint Filing Agreement be included as an exhibit to any such statement and any such amendment. The undersigned further agree that each party hereto is responsible for the timely filing of such statements and amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning any other filing party, unless such party knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 26th day of July, 2017.

 

NOVARTIS PHARMA AG

 

 

 

/s/ Jean-Baptiste Emery

 

Name: Jean-Baptiste Emery

 

Title: Authorized Signatory

 

 

 

/s/ Stefan Thommen

 

Name: Stefan Thommen

 

Title: Authorized Signatory

 

 

 

NOVARTIS AG

 

 

 

/s/ Christian Rehm

 

Name: Christian Rehm

 

Title: Authorized Signatory

 

 

 

/s/ Katja Roth Pellanda

 

Name: Katja Roth Pellanda

 

Title: Authorized Signatory

 

 

10